Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.

Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H.

Sci Rep. 2013;3:1065. doi: 10.1038/srep01065. Epub 2013 Jan 15.

2.

Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.

Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, Toyoda K, Murata M, Hayashi J.

Aliment Pharmacol Ther. 2016 Jan;43(1):114-24. doi: 10.1111/apt.13431. Epub 2015 Oct 26.

3.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

4.

Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma.

Fujiyoshi M, Kuno A, Gotoh M, Fukai M, Yokoo H, Kamachi H, Kamiyama T, Korenaga M, Mizokami M, Narimatsu H, Taketomi A; Hepatitis Glyco-biomarker Study Group.

J Gastroenterol. 2015 Nov;50(11):1134-44. doi: 10.1007/s00535-015-1063-2. Epub 2015 Mar 15.

PMID:
25773774
5.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
6.
7.

Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.

Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J.

Antivir Ther. 2015;20(2):185-92. doi: 10.3851/IMP2805. Epub 2014 Jun 18.

PMID:
24941012
8.

IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.

Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T.

World J Gastroenterol. 2012 Sep 21;18(35):4892-7.

9.

Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.

El Raziky M, Attia D, El Akel W, Shaker O, Khatab H, Abdo S, Elsharkawy A, Esmat G.

Arab J Gastroenterol. 2013 Sep;14(3):94-8. doi: 10.1016/j.ajg.2013.08.005. Epub 2013 Oct 10.

PMID:
24206736
10.

Aminoadamantanes for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 May 3;(5):CD010125. doi: 10.1002/14651858.CD010125.pub2. Review.

PMID:
24793264
11.

Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.

Mendoza J, Trapero-Marugán M, González-Moreno L, Jones EA, Gómez-Domínguez E, Moreno-Otero R.

Rev Esp Enferm Dig. 2010 Jul;102(7):426-34.

12.

Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.

Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A, Pirisi M, Smirne C, Colletta C, Traverso A, Mazzucco D, Ciccone G, Simondi D, Rizzetto M, Saracco G.

Eur J Gastroenterol Hepatol. 2014 Jan;26(1):52-8. doi: 10.1097/MEG.0b013e328362dc99.

PMID:
23719564
13.

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL; Halt-C Trial Group.

Clin Gastroenterol Hepatol. 2009 Feb;7(2):219-26. doi: 10.1016/j.cgh.2008.10.034. Epub 2008 Nov 7.

14.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
15.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

16.

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003617. doi: 10.1002/14651858.CD003617.pub2. Review.

PMID:
23440791
17.

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2006 Dec;44(6):1675-84.

18.

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.

Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S.

Aliment Pharmacol Ther. 2012 Jun;35(12):1434-42. doi: 10.1111/j.1365-2036.2012.05109.x. Epub 2012 Apr 24.

19.

Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.

Pinzone MR, Zanghì AM, Rapisarda L, D'Agata V, Benanti F, Spartà D, Nunnari G, Cacopardo B.

Eur Rev Med Pharmacol Sci. 2014 Dec;18(2 Suppl):11-5.

20.

Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.

Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.

Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12.

PMID:
24126097

Supplemental Content

Support Center